Intellia Therapeutics (NTLA) Stock Price
Intellia Therapeutics Price
Revenue has compounded at 27.3% per year over the past 10 years to 67.67 M USD. Intellia Therapeutics's net margin stands at -609.9%, up from -785.8% several years earlier. Analysts set a median price target of 20.50 USD, implying 62.3% above the current price. Of 24 analysts, 14 rate the stock a buy — an overall Buy consensus.
Intellia Therapeutics stock price
Intellia Therapeutics business model & stock analysis
Frequently asked questions about Intellia Therapeutics
Intellia Therapeutics Inc. is a leading biotechnology company specializing in the development of potentially curative medicines based on CRISPR/Cas9 gene editing technology. The company's business model revolves around using this innovative gene editing platform to develop and commercialize novel therapies for a wide range of genetic diseases. Intellia Therapeutics aims to leverage its expertise in genome editing to provide transformative treatments that address patients' unmet medical needs. By harnessing the power of CRISPR/Cas9, Intellia Therapeutics aims to revolutionize the biotechnology industry and make significant advancements in precision medicine.
Intellia Therapeutics Inc is primarily active in the biotechnology industry.
The main competitors of Intellia Therapeutics Inc in the market include CRISPR Therapeutics AG, Editas Medicine Inc, and Sangamo Therapeutics Inc.
Intellia Therapeutics Inc is a biotechnology company based in Cambridge, Massachusetts. Founded in 2014, Intellia is focused on developing CRISPR/Cas9 genome editing technology for therapeutic applications. The company aims to revolutionize medicine by harnessing the power of CRISPR to eradicate genetic diseases, create more effective and precise treatments, and improve patient outcomes. Intellia has pioneered several groundbreaking research initiatives and strategic collaborations, including partnerships with leading pharmaceutical companies. With a strong commitment to innovation and scientific excellence, Intellia Therapeutics Inc continues to make significant strides in advancing the field of gene editing and unlocking potential cures for debilitating genetic disorders.
Intellia Therapeutics Inc has achieved several significant milestones. Notably, the company successfully entered into a collaboration with Novartis to develop and commercialize CAR-T cell therapies utilizing its CRISPR/Cas9 technology. Additionally, Intellia Therapeutics became the first company to demonstrate in vivo editing using CRISPR/Cas9 in a non-human primate model. Furthermore, the company received FDA clearance for its Investigational New Drug (IND) application for the treatment of transthyretin amyloidosis, which marked a crucial step in developing potential therapies for this rare disease. Intellia Therapeutics continues to make progress in leveraging its innovative gene editing platform to pave the way for novel therapeutic interventions.
Intellia Therapeutics Inc primarily operates in the United States.
Intellia Therapeutics Inc is a leading biotechnology company that focuses on developing CRISPR/Cas9 genome editing technology. The company's corporate philosophy revolves around innovation, collaboration, and scientific excellence. Intellia Therapeutics is committed to revolutionizing medicine by utilizing CRISPR/Cas9 to potentially treat various genetic diseases. With a mission to develop curative therapeutics, Intellia Therapeutics aims to transform the lives of patients and their families. The company values integrity, diversity, and dedication to science-driven advancements. Through its cutting-edge research and passionate team, Intellia Therapeutics is committed to delivering groundbreaking solutions and making a lasting impact in the field of gene editing.
Analysts currently set an average price target of 23.40 USD for the Intellia Therapeutics stock (median: 20.50 USD), implying +82.5 % versus the latest price. The consensus is based on 24 analyst ratings.
24 analysts currently rate the Intellia Therapeutics stock: 14 recommend buying, 7 holding and 3 selling. For 2026, analysts expect Intellia Therapeutics to generate revenue of 50.26 M USD and earnings per share of -3.20 USD.
Converted at the current exchange rate, the Intellia Therapeutics share trades at 11.27 EUR (12.63 USD).
The Intellia Therapeutics share (NTLA) is listed on 7 stock exchanges, including: NASDAQ (NTLA), London (0JBU.L), SIX (Zürich) (38I.SW), Frankfurt (38I.F), München (38I.MU), Düsseldorf (38I.DU).
Intellia Therapeutics Inc is a biotechnology company based in Cambridge, Massachusetts, focused on developing therapies for genetic diseases. The company utilizes CRISPR/Cas9 gene editing technology to make targeted changes in the human genome and potentially develop life-changing therapies. Intellia is currently focusing on the treatment of liver diseases such as hereditary transthyretin amyloidosis (ATTR) and hemophilia, which is based on a malfunction of the blood clotting system. The company is also dedicated to developing therapies for cancer and rare genetic diseases. Intellia's main products are genetic therapies that aim to remove or repair disease-causing mutations in patients' genomes. These therapies utilize CRISPR/Cas9 gene editing technology to cut and efficiently edit DNA. The company has also formed partnerships with other biotechnology and pharmaceutical companies to apply this technology to other areas of medicine and research. Intellia has a pipeline of therapies in various stages of development. The company collaborates closely with academics and industry experts to explore and expand the technology and the benefits of clinical medical studies and more precise diagnostic procedures. Intellia's business strategy is to bring significant therapeutic innovations to market by leveraging its expertise in CRISPR/Cas9 technology. The company has a strong financial position that allows it to invest in the development of innovative therapies and technologies. It has also formed strategic partnerships with companies such as Regeneron Pharmaceuticals and Novartis to accelerate research and development. Intellia believes that its technology has the potential to revolutionize the treatment of diseases and create immense opportunities for scientists, patients, and investors over time. The company is committed to utilizing CRISPR/Cas9 technology to develop groundbreaking therapies that improve patients' lives and advance medical research.
The expected revenue of Intellia Therapeutics is 50.26 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Intellia Therapeutics is -346.85 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Intellia Therapeutics is currently -3.95. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Intellia Therapeutics stock.
The price-to-sales ratio (P/S) of Intellia Therapeutics is currently 27.23. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Intellia Therapeutics stock.
The Eulerpool Quality Score for Intellia Therapeutics is 4/10.
The ISIN of Intellia Therapeutics is US45826J1051. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Intellia Therapeutics is A2AG6H. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Intellia Therapeutics is NTLA. The ticker symbol is used to trade Intellia Therapeutics shares on the stock exchange.
Intellia Therapeutics stock
Intellia Therapeutics Peer Group
Intellia Therapeutics Ticker
Intellia Therapeutics FIGI
All fundamentals and in-depth analysis of Intellia Therapeutics
Our stock analysis for Intellia Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Intellia Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.